>IDIX – Excuse my laziness to look this up. I wonder why idix dropped so much over the last 12 months.< In descending order of importance (IMO): 1. Question surrounding the viability of NM283 on account of the dose reduction due to GI side effects. 2. The early success of VRTX’s VX-950 in treating HCV. 3. General market conditions. -- I think IDIX is a great long-term buy at the current price. Regards, Dew